← Library
Orforglipron
Research Use
Also known as LY3502970
Function
Primary
Obesity · Type 2 Diabetes (investigational)
Mechanism
Non-peptide oral GLP-1 receptor agonist — preserves GLP-1 pharmacology without injection or food restrictions.
Evidence
Clinical RCT (Limited)
Research
Phase 2 weight loss ~14.7% at 36 wk
Dosing
Range
12–45 mg/day (trial)
Frequency
Daily oral
Route
Oral
Cycling
Continuous with titration.
Benefits
- ·Oral convenience (no food/water restriction)
- ·HbA1c reduction
- ·Weight loss without injection
Risks
- ·GI side effects
- ·LFT elevations (monitor)
- ·Heart rate increase
Contraindications
- ·MTC / MEN-2 (class)
- ·Pregnancy
Regulatory
Investigational (Eli Lilly, Phase 3 ATTAIN/ACHIEVE)
Functional Groups
Cited Works
- Wharton S et al. Daily Oral Orforglipron for Obesity — Phase 2. N Engl J Med. 2023;389:877.source